ilaprazole + amoxicillin + clarithromycin + furazolidone + doxycycline + bismuth-The Third Xiangya Hospital of Central South University-Helicobacter pylori infection

This combination therapy refers to a bismuth-containing quadruple therapy (BQT) protocol studied at The Third Xiangya Hospital of Central South University for the rescue treatment of Helicobacter pylori infection. The regimen typically involves the proton pump inhibitor ilaprazole, colloidal bismuth tartrate, and doxycycline, combined with either amoxicillin, clarithromycin, or furazolidone, although the user's designation lists them collectively. The mechanism of action is multi-targeted: ilaprazole inhibits the H+/K+-ATPase to reduce gastric acidity and optimize antibiotic efficacy, bismuth provides direct bactericidal effects and mucosal protection, and the antibiotics (amoxicillin, clarithromycin, furazolidone, and doxycycline) disrupt bacterial cell wall synthesis, protein synthesis, and DNA stability. This intensive approach is designed to overcome antibiotic resistance in patients who have failed multiple previous eradication attempts and has been evaluated in clinical trials alongside adjuvants such as egg yolk antibodies (IgY).

Other names

Bismuth quadruple therapy rescue regimenBQT rescue therapy